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ABSTRACT 
The combination of high-performance liquid chromatography and mass spectrometry (LC/MS) has 
had a sign cant impact on drug development over the past decade. Continual improvements in LC/MS 
interface technologies combined with powerful features for structure analysis, qualitative and 
quantitative, have resulted in a widened scope of application. These improvements coincided with 
breakthroughs in combinatorial chemistry, molecular biology, and an overall industry trend of 
accelerated development. The use of high-performance liquid chromatography combined with mass 
spectrometry (HPLC–MS) or tandem mass spectrometry (HPLC–MS–MS) has proven to be the 
analytical technique of choice for most assays used in various stages of new drug discovery. A 
summary of the key components of HPLC–MS systems, as well as an overview of major application 
areas that use this technique as part of the drug discovery process, will be described here. This review 
will also provide an introduction into the various types of mass spectrometers that can be selected for 
the multiple tasks that can be performed using LC–MS as the analytical tool. The strategies for 
optimizing the use of this technique and also the potential problems and how to avoid them will be 
highlighted. 
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1. Introduction: 
Current trends in drug development emphasize 
high volume approaches to accelerate lead 
candidate generation and evaluation. Drug 
discovery-based technologies that involve 
bimolecular screening and combinatorial 
chemistry paved the way, resulting in shortened 
timelines and the generation of more 
information for more drug candidates. The 
impact on the overall drug development cycle 
has been sign cant, creating unprecedented 
opportunities for growth and focus, particularly 
in the analytical sciences The use of high-
performance liquid chromatography combined 
with mass spectrometry (HPLC–MS) or tandem 
mass spectrometry (HPLC–MS–MS) has proven 
to be the analytical technique of choice for most 
assays used in various stages of new drug 
discovery 1.New drug discovery can be defined 
as the process whereby compound libraries are 
screened, then hits are selected and modified to 
become leads that are optimized until a 
compound emerges that can be developed into a 
drug candidate. HPLC–MS and HPLC–MS–MS 
are used for the analysis of newly synthesized 
compounds that become part of a compound 
library. These assays check that the correct 
compound has been synthesized and that the 
purity is sufficient to be used in the library. In a 
second stage, various physical and chemical 
properties (e.g. physiological solubility, 
permeability and chemical stability) of these 
new chemical entities (NCEs) are assessed and 
HPLC–MS is often used for these assays 
 
2. Principles of LC–MS: The elements of an 
LC–MS system include the auto sampler, the 
HPLC system, the ionization source (which 
interfaces the LC to the MS) and the mass 
spectrometer. Ideally, these elements are all 
under the control of a single computer system. 
HPLC is a common technique, so it will not be 
described here. It should be noted that to 
interface HPLC with MS, there are some 
restrictions on the flow rate and mobile phases 
that can be used .Typical reversed phase HPLC 
systems connected to MS would use some 
combination of water and either methanol or 
acetonitrile as the mobile phase. There are 
limitations on the mobile phase modifiers; for 
example, in most cases the modifiers have to be 
volatile. Mobile phase modifiers are chemicals 
added to the mobile phase that are used 
primarily to improve the chromatography of the 
Ana lutes of interest. Typical mobile phase 
modifiers would include ammonium acetate, 
acetic acid and formic acid. There are multiple 
articles that focus on the HPLC parameters that 
are important in LC–MS assays. 
3. Types of mass spectrometers: 
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There are many types of mass spectrometers 
available for interfacing with HPLC2 , one of the 
more common systems used for HPLC–MS is 
the single quadruple mass spectrometer; this 
system will provide a mass spectrum for each 
chromatographic peak that elutes from the LC 
column and is analysed by the MS system. The 
second type of system shown is the time-off 
light (TOF) mass spectrometer, which has the 
added capability of providing a higher mass 
resolution spectrum from each component that is 
assayed. The third system shown is the triple 
quadruple MS–MS system, which is most often 
used for bio analytical assays but can also be 
used for metabolite identification assays 3. The 
fourth MS system is called an ion-trap mass 
spectrometer and has the unique capability of 
producing MS data that are important when 
performing structural elucidation assays. In 
addition to these four types of mass 
spectrometers, there are a growing number of 
additional types, including hybrid systems that 
have unique capabilities. Hybrid mass 
spectrometers combine two of the basic types of 
mass spectrometer to make a specialty system; 
an example of a hybrid mass spectrometer is the 
‘Q-TOF’ MS–MS system, which combines a 
quadruple mass spectrometer with a TOF mass 
spectrometer.  
 
4. Integration of LC/MS into Drug 
Development 
Liquid chromatography/mass spectrometry 
(LC/MS)-based techniques provide unique 
capabilities for pharmaceutical analysis. LC/MS 
methods are applicable to a wide range of 
compounds of pharmaceutical interest, and they 
feature powerful analytical gores of merit 
(sensitivity, selectivity, speed of analysis, and 
cost effectiveness). These analytical features 
have continually improved, resulting in easier to 
use and more reliable instruments. These 
improvements were timely and coincided with 
the aforementioned developments in the 
pharmaceutical industry. 
4.1. Emerging Analytical Needs: Perhaps a 
major cause of these opportunities is the fact that 
the rate of sample generation far exceeded the 
rate of sample analysis. To put this factor in 
perspective, consider the following example that 
deals with combinatorial chemistry. Prior to the 
advent of combinatorial chemistry technologies, 
a single bench chemist was capable of 
synthesizing ca. 50 ®nil compounds per year, 
depending on the synthesis. Today, chemists are 
capable of generating well over 2,000 
compounds per year, using a variety of 
automated synthesis technologies. If traditional 
approaches to analytical support were 
maintained, then analysts would outnumber 
chemists by nearly 40 to 1! 
* An earlier availability of information leads to 
faster decision making. 
* Integration of instrumentation with 
information network is a popular approach for 
combining high throughput analytical 
information generation with Drug-candidate 
screening. 
* Software is a powerful resource for the 
coordination of analysis events and the 
management and visualization of data. 
4.2. Partnerships and Acceptance: What has 
happened in the pharmaceutical industry during 
this relatively short time span is truly 
remarkable. With the advent of advanced 
technologies responsible for increasing the rate 
of sample generation, there is strong motivation 
to respond with LC/MS-based analysis 
Techniques. The understanding of principles, 
fundamentals, operation, and maintenance 
enabled researchers to improve analytical 
performance. Here, the power of `seeing is 
believing'' led to lower barriers of acceptance as 
well as to a new breed of practitioners 
 
5. Systematic LC/MS Metabolite 
Identification in Drug Discover: 
The study of how a drug is absorbed, distributed, 
metabolized, and eliminated by the body is a 
vital but costly and time-consuming step in the 
drug discovery process. Metabolism can dictate 
the rate of absorption into the body, lead to the 
production of new and possibly toxic species, or 
activate the drug. For example, morphine’s 
effect is primarily due to one of its glucuronide 
conjugate metabolites .Until recently, metabolite 
identification only took place once a compound 
had been chosen for drug development. 
However, the discovery of a toxic metabolite 
can set a research program back significantly. 
As a result, many pharmaceutical companies are 
now conducting metabolite identification studies 
in the early phases of drug candidate selection. 
But this is no easy task. The metabolism of a 
drug within a test animal can be extremely 
complex, involve multiple enzymatic pathways, 
and lead to a range of compounds with varying 
concentrations (7). Other drugs have one or two 
major metabolic pathways that dominate their 
metabolism, but several minor pathways can 
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produce at least one metabolite. We have seen 
>30 detectable, and theoretically identifiable, 
metabolites form from a single compound. 
 
Figure1: Diagram showing how the Automated Legend Identification System (ALIS) system 
uses MS for high throughput activity screening. 
5.1. Chemistry-library synthesis: In a typical 
arrangement, an HPLC–MS system will be used 
to provide information on compound identity 
and purity as a first step in building a discrete 
compound library. A common system would 
have an in-line UV detector for the purity 
assessment, as well as the MS system for the 
compound identity confirmation. The mass 
spectrometer is often either a single quadruple or 
a TOF system. These systems are often highly 
automated; for example, Isbell et al. 24 describe a 
high throughput procedure that combines an 
automated compound purification procedure 
with the compound analysis step. This process is 
based on a combination of HPLC–MS with 
software-controlled fraction collectors that are 
triggered on the basis of the observed or 
expected m/z response of the compound of 
interest to make the whole process highly 
automated. 
5.2. In vitro screening: One of the more 
commonly used in vitro screens is the human 
colon adrenal carcinoma cell line (Caco-2), 
which is used for the measurement of the 
permeability potential of a compound – one of 
the aspects of the absorption process 31.There are 
several reports on how LC–MScan be used for 
the analysis of Caco-2samples 34. In one 
example, Fung et al.35 described a higher 
throughput assay for Caco-2 samples that was 
capable of handling 100 compounds per week, 
based on HPLC–MS–MS using a triple 
quadruple MS system. One of the tools required 
to assay this many compounds was an MS 
method development tool, provided as part of 
the software package by the instrument vendor; 
this tool is important for applications that require 
the system operator to develop discrete MS–MS 
transitions for each compound that is assayed. 
Another way in which Fanged al. 32 improved 
the assay efficiency was by reducing the number 
of samples that had to be injected through the 
elimination of a calibration curve. The Caco-2 
results for a given compound (permeability 
calculation) are based on the ratio of two 
samples; therefore, they demonstrated that the 
ratio of the MS responses of the two samples 
could be used instead of the ratio of the 
concentrations of the two samples, thereby 
eliminating the need for a calibration curve for 
each compound. Another higher throughput in 
vitro assay is the one used to assess a potential 
of a compound to inhibit of one or more of the 
human cytochrome P450 isoforms (CYPs); this 
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step is important to determine a compound’s 
potential for drug–drug interactions. In this case, 
the assay can be optimized to be high throughput 
because the analysis does not measure the 
compound that is being tested. There have been 
several reports in recent years describing how 
HPLC–MS–MS can be used for providing 
higher throughput assays to support various 
CYP screens for enzyme inhibition .In a recent 
example, Pang et al. described a high throughput 
assay based on HPLC–MS–MS to screen for 
five important CYP ribozymes – CYP 3A4, 
CYP2D6, CYP2C9,CYP2C19 and CYP1A2.  
5.3. High-throughput screening: Although 
HTS is usually performed using various 
fluorescence procedures to look for compounds 
that have the desired in vitro activity, there have 
been some examples where mass spectrometry 
has been used for this step in the new drug 
discovery process As discussed by Flab and 
Jindal 26, the strategy uses mixtures of 
compounds plus a target protein to identify 
potential lead compounds for a therapy based on 
compound so that interact with the target 
protein. This high throughput screen uses 
HPLC–MS to identify the ligand compounds; in 
this case the mass spectrometry system is a TOF. 
5.4. ADME–PK screening: Perhaps the most 
common use for LC–MS in new drug discovery 
is for the various ADME studies that make up 
the majority of the effort provided by the drug 
metabolism and pharmacokinetic (DMPK) 
groups in their participation in the process 27–30. 
There are several in vitro ADME screens, 
followed by various in vivo preclinical ADME–
PK screens. These screens are almost always 
supported by LC–MS assays.  
 
6. In vitro screen is the metabolic stability 
assay: 
The goal of this assay is to provide a prediction 
of the in vivo intrinsic clearance of a compound. 
Aniseed and Thacker recently reviewed the area 
of metabolic stability assays and also provided a 
good summary of the relative importance of the 
major CYP isoforms for human metabolism. 
Generally, the metabolic stability assays are 
based on the incubation of the compound in the 
presence of either human liver microtomes or 
human hepatocytes; in either case, the samples 
are typically assayed using a compound-specific 
analysis based on HPLC–MS–MS (usually with 
a triple quadruple system). Several examples of 
high throughput metabolic stability assays based 
on LC–MS have been reported. In an early 
example, Korfmacher et al. 44 described an 
automated assay based on a single quadruple 
LC–MS system that used an automated data 
analysis system and could test 75 compounds 
per week for metabolic stability. Wring et al. 36 
described a system for metabolic stability that 
included automated liquid handling and an LC–
MS assay based on a triple quadruple mass 
spectrometer that was capable of handling 50 
compounds per week. More recently, Xuet al. 30 
reported a highly automated system based on 
robotic sample preparation of the test compound 
plates, as well as the human liver microsomal 
incubations with three time points selected 
(5,15and 30 min) in addition to the time zero 
point. All samples were measured in triplicate to 
improve the reliability of the results. The assay 
was based on a single quadruple LC–MS system 
that included an eight-probe auto sampler and 
eight HPLC columns in a parallel mode. This 
system was able to assay 240 samples per hour, 
which enabled up to 176 test compounds to be 
evaluated per day. In addition to the high 
throughput assay, the authors described 
automated data processing tools that enabled the 
analysis of this data in a short time frame. 
 
7. LC/MS Metabolite Identification in Drug 
Discovery: 
MS has emerged as an ideal technique for the 
identification of such structurally diverse 
metabolites. When coupled with on-line HPLC, 
the technique is extremely robust, rapid, 
sensitive, and easily automated 11. Not 
surprisingly, LC/MS and LC/MS/MS have 
become the methods of choice for 
pharmacokinetic studies, yielding concentration 
versus time data for drug compounds from in 
vivo samples such as plasma 2.Instruments and 
software packages. Furthermore, just as in a 
police investigation Nevertheless, identifying 
metabolites remains a time-consuming process 
because arrange of instrumental techniques and 
software applications are needed to obtain the 
appropriate data. The analyst must be quite 
experienced to handle these various the data is 
rarely obvious or completely conclusive, but 
rather requires previous experience to unravel it. 
For all these reasons, interpreting the data is 
typically the largest bottleneck in metabolite 
identification. 
In this report, we present the choices and 
decisions involved in metabolite identification 
and how they can be merged into a systematic 
approach. The discussion covers the tools and 
techniques available to the mass spectra merits, 
the complementary natures of different types of 
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mass spectrometers, and innovative software 
that reduces the size of data sets. This new 
approach greatly increases sample throughput 
and turnaround time for useful information. A 
complete metabolite identification study is also 
described, which uses all of the techniques and 
instrumentation discussed. 
 
The flow chart in the basic approach to 
metabolite identification: 
 
 
 
8. Systematic approach to metabolite 
identification and characterization: 
The approach assumes that it is possible to 
predict numerous common alterations to the 
drug such as oxidation and oxidative 
conjugation. Typically, the compounds under 
investigation in a single drug discovery project 
is structurally very similar because a prospective 
lead compound's structure is 'fine-tuned' for 
better selectivity and potency toward the 
receptor of interest. Therefore, the mass 
spectrometric that analyses compounds in an 
analogous series quickly learns the most 
common metabolic alterations to the parent 
structure and any novel modifications. This 
experience and information allows for a guided 
analysis with targeted searches for expected 
metabolites. (To ensure that novel metabolites 
caused by less-common metabolic pathways are 
detected precursor ion scanning is available.) 
 
9. Techniques and instrumentation: 
An exhaustive description of all available MS 
instruments and their modes of operation is 
beyond the scope of this article and not 
necessary to appreciate the strategies being 
applied here. However, a basic knowledge of a 
few types of major systems and their important 
modes of operation is required and included. 
9.1. Tandem MS: Tandem MS is the 
cornerstone of metabolite identification 
12,14.Tandem MS actually covers a variety of 
scanning techniques including product ion, 
precursor ion, and neutral-loss scanning. 
Tandem mass spectrometers usually contain an 
isolation stage and a fragmentation stage within 
the same device. Although many different ways 
exist to complete a tandem MS experiment, all 
of them follow the same basic series of events. 
First, the ion of interest is isolated on the basis 
of its m/z ratio and then passed into the collision 
cell, a region of local high pressure. (In trapping 
instruments, the isolation and fragmentation 
normally take place within the same space 
between electrodes, and the stages are separated 
by time rather than space.) The collision cell is 
filled with an inert gas such as argon or helium, 
and a voltage is applied. Energized ions collide 
with the target gas, and each collision imparts a 
small amount of energy to the ion until sufficient 
energy is deposited to cleave an internal bond or 
bonds. The resulting ion fragments pass out of 
the cell and into the detector. 
9.2. Targeted product ion analysis: In drug 
discovery, each new compound normally arises 
from a small alteration to an initial lead template 
that was discovered in a receptor-binding assay. 
The final compound may bear very little 
similarity to that initial lead, but it has a lineage 
that stretches back to the initial compound. 
Consequently, after the first one or two 
compounds have been fully assayed, any 
structural regions or 'soft spots' within the 
compounds in a drug series, which are highly 
susceptible to metabolism, are determined. 
Common metabolic alterations can be predicted, 
and a list of expected metabolites can be 
compiled, on the basis of a previously analysed 
series. By combining this list with a list of 
suspected metabolites identified by precursor 
and neutral-loss scan data, a series of ions can be 
targeted for production analysis. 
Any type of mass spectrometer capable of 
product ion scanning can be used at this point, 
including a triple quadruple. Thus, all of the 
experiments discussed so far can be completed 
using a single instrument. However, to localize 
alterations within a molecule to a specific site, 
additional stages of tandem MS (MS) require a 
more specialized mass spectrometer. 
9.3. Determining sites of modification: 
Multiple stages of MS can provide large 
amounts of structural information regarding each 
analyse, thereby allowing for a more detailed 
characterization of the metabolites15,16. 
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Completing MS experiments requires a mass 
spectrometer that can capture and store ions 13, 15, 
16. While the ions are stored, they can be 
subjected to excitation and collisional 
fragmentation. The trapping instrument can then 
capture the resultant fragment ions, which can 
then be forced to undergo further fragmentation. 
The second-generation mass spectrums will now 
give structural information regarding the isolated 
fragment, allowing easier characterization of 
that ion. Because this procedure can be applied 
to each of the initial parent ion fragments, 
detailed structural information can be acquired 
rapidly. This technique often allows the isolation 
of a small region of the parent ion molecule that 
has been modified and, in some cases, even the 
individual atom that are different. At present, the 
Fourier transform (FT) and the quadruple ion 
trap mass spectrometers are the only trapping 
mass spectrometers available FTMS instruments 
are not yet capable of high throughput on a 
regular basis because they are expensive and 
require skilled operators. Thus, cheaper and 
simpler quadruple ion trap mass spectrometers 
are typically used for these types of trapping 
experiments. 
9.4. Identification of a dosed compound: With 
the basics of instrumentation and techniques 
described, a full metabolite identification study 
of a compound dosed in vivo can be examined. 
Sprague-Daley male rats were dosed 
intravenously with Schering-Plough discovery 
compound SCH X at 2 mg/kg body weight and 
orally at 10 mg/kg. Urine and bile were collected 
over 24 h at regular time intervals. Before 
analysis, the individual time point samples for 
each animal were pooled for each dosing region 
to generate one 0- to 24-h  bile and one 0- to 24-
h urine sample. No further sample preparation 
was performed. Minimal sample clean-up is 
used because the nature, number, and 
concentrations of metabolites present are 
unknown, and it is therefore impossible to 
determine if any will be lost during a sample 
preparation procedure. 
9.4.1. Step 1: Collecting precursor ion scan 
and neutral-loss data: After sample 
preparation, a list of potential metabolites in the 
bile and urine sample needs to be compiled from 
precursor ion and constant neutral-loss analyses 
completed on a triple quadruple mass 
spectrometer. If the compound had been radio 
labeled, an online radioactivity detector would 
have also been used to mark time points where 
the compound elutes within the chromatographic 
run. Figure A demonstrates the type of data 
recorded in a precursor scan. At least eight 
apparent metabolites are evident in a single 
experiment, solely on the basis of the fragment 
ions' similarity to those produced by the parent 
compound standard. An additional five possible 
metabolites were found in the urine via 
precursor ion scanning data (data not shown). 
The total analysis took 44 min and required one 
bile and one urine injection to detect all 13 
metabolites. Typically, more than a single series 
of fragment ions are scanned, corresponding to 
characteristic fragments from the top, middle, 
and lower portions of the parent compound. 
Common alterations to these fragments, such as 
hydroxylation, are monitored by looking for 
precursors of the analyse at the native fragment 
mass and fragments 
Corresponding to the metabolic hydroxylations, 
which are 16 Da higher.
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Figure.2: Precursor ion and constant neutral-loss scan experiments. 
(a) Precursor ion scan and (b) constant neutral-loss (176 Da) scan experiments using rat bile. In both cases, the 
data are shown as an individual mass trace.  Each trace is labeled with the putative metabolite’s potential 
identity on the basis of their detected mass 
9.4.2. Step 2: Product ion analysis of 
potential metabolites: The product ion data in 
the next step were acquired on the Q-TOF 
mass spectrometer, but a triple quadruple or 
quadruple ion trap mass spectrometer could 
also have been used. The Q-TOF instrument 
was used to examine a list of 'expected' 
metabolites that had been previously observed 
for analogy from this compound series and 
included+16 Da (hydroxylation), '14 Da (DE 
methylation), and +32 Da (hydroxylation). In 
addition, any putative metabolites identified 
by the precursor ion and neutral-loss scans 
also underwent product ion analysis. The rapid 
scanning abilities of the Q-TOF instrument 
allow several product ion experiments to be 
performed in rapid succession in a single LC 
run. 
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Figure.3. Product ion scan data used to identify several putative metabolites first detected in 
Figure 2. (a) Mass chromatograms for each of the examined metabolites. The individual traces are labeled with 
the potential identity of the metabolite on the basis of information from Figure 2 experiments. (b) Tandem MS 
spectra from peaks Ian II. 
 
10. Structural elucidation of metabolites by 
MS.: Because of constraints due to space, 
expense, and complexity, the quadruple ion trap 
is the instrument of choice for MS experiments 
in a typical metabolite identification laboratory. 
For an MS experiment, the masses of the intact 
metabolite and a related fragment ion are 
required. Because this information comes from 
the MS/MS experiments described in Step 2, 
MS3 experiments can be set up directly on the 
instrument without any further 
experimentation.MS3 often gives data sufficient 
to determine the type of metabolite modification 
and indicate which parts of the molecule were 
changed. In most cases however, especially for 
molecules that only break into a few large 
fragments, MS4 or evenMS5 may be required to 
locate the site of modification, an O-glucuronide 
metabolite had to undergo MS5 before locating 
the site of oxidation. In each trace, the fragment 
ion that will undergo additional fragmentation is 
highlighted. Thus, this technique quickly 
pinpoints a very small area that has been altered. 
 
Figure.4.MS1 through MS5 data from the analysis of an O-glucuronide metabolite.  
Each trace shows the next level of tandem MS in the sequential cleavage observed in the metabolite
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10.1. Accurate mass measurement: The power 
of accurately determining the mass of a 
metabolite lies in being able to determine a list 
of possible empirical formulae. Obviously, the 
more accurate the mass measurements, the fewer 
degrees of freedom are available to the software 
calculating a formula, and the shorter the list of 
possibilities. Accurate mass product ion data 
further limits the number of possible formulae 
by providing data that are even more specific to 
the empirical formulae calculator. Product ion 
experiments narrow the site of modification to 
small portion of the molecule and an accurate 
mass determination of this fragment limits the 
software to fewer structural possibilities. 
Furthermore, the operator normally has prior 
knowledge of the parent compound's structure, 
which limits the number and types of atoms the 
software should take into consideration. Until 
recently, accurate mass measurement required 
double-sector instruments or Fourier transform 
ion cyclotron resonance instruments, which are 
very large, complex, and expensive. However, 
the advent of less complex and expensive bench 
top TOF instruments and hybrid instruments 
such as Q-TOF has allowed the application of 
accurate mass measurement in the metabolite 
identification laboratory. 
 
 
 
 
Figure.5.: Accurate mass data from monkey bile.  
a) Raw data and (b) accurately Measured data after the external reference mass calibration was applied. The 
partial chemical structure shows the two most likely alterations that may have occurred 
 
11. Still searching: 
The strategies detailed in this report are the 
result of more than two years of work. They are 
not meant to exhaustively identify every 
metabolite present within in vivo samples, but 
rather to rapidly and accurately identify sites of 
metabolic liability that might affect 
pharmacokinetic measurement results and 
detect the formation of possibly toxic 
metabolites. Therefore, only major metabolites 
are identified, but the definition of a major 
metabolite differs widely among researchers. 
Because ~50%of our samples are radioactive, 
our laboratory definition of 'major' includes any 
resolved radioactive peak that constitutes 5% or 
greater of the overall radioactivity detected in 
that experiment. However, inevitably, other 
low-level metabolites are automatically 
detected using the prescribed strategies. 
12. 10 years of MS instrumental 
developments – Impact on LC–MS/MS in 
clinical chemistry: 
Within the past decade mass spectrometry (MS) 
has entered the clinical laboratory and is now 
being used for a wide range of applications. 
The technique can be considered essential for 
the determination of many clinically relevant 
analyses in combination with either gas 
chromatography (GC) or liquid 
chromatography (LC). The power of MS, 
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especially when coupled to LC, is recognized 
by clinical laboratories worldwide and the 
growing versatility of these systems puts 
clinical laboratories in a position where they 
can provide a rapid response to changing 
clinical needs. Even though it requires some 
effort much needed assays can be developed in 
the laboratory instead of waiting for a 
manufacturer to respond. Furthermore it is 
undoubted that these techniques pro-vide a 
higher level of sensitivity and specificity in 
many cases compared to other analytical 
techniques and that pateend care has benefited 
from their use. Besides specificity and 
sensitivity the ability of these techniques to 
measure multiple analyses  simultaneously is a 
tremendous benefit of LC coupled to MS 
methods since many other techniques are 
limited to determine one analyse at a time. 
Especially these multi-component methods can 
make the purchase of a liquid chromatography 
tandem mass spectrometry (LC–MS/MS) 
instrument cost-effective. Improvements in 
automation and software help clinical 
laboratories to deal with staffing and service 
issues. 
12.1. Ion source developments: Coupling MS 
to LC was a very important motivation in the 
development process of atmospheric pressure 
ion sources. Systems where the samples are 
introduced via a liquid stream achieved wide 
acceptance and commercial importance. Electro 
spray ionization (ESI) and atmospheric 
pressure chemical ionization (APCI) are the 
liquid introduction ion sources which had the 
most commercial success and enormous 
improvements were made in the first 15 years 
after their invention during the mid-1980s. Two 
excellent reviews were published dealing with 
the evolution of these ionization sources 16,17. 
Based on these developments multimode ion 
sources were introduced on the market by 
various manufacturers. In addition the 
atmospheric pressure photo ionization (APPI) 
ion source was developed and improved within 
the last 10 years. Therefore more detailed 
information about multimode and APPI ion 
sources will be presented in the following 
chapters and their suitability regarding their 
application to clinical chemistry will be 
discussed. Apart these commercially successful 
LC–MS ion sources very creative approaches 
were investigated for the hyphenation of LC 
with MS using other available ion sources. 
Research scientists especially set their focus on 
various desorption techniques. The 
combination of LC with matrix-assisted laser 
desorption ionization (MALDI) started to 
emerge in the mid-1990s 18,19 and continuous 
effort was undertaken to further improve the 
technique 20–25. Very recently LC–MS methods 
were described using desorption electro spray 
ionization (DESI) 26 and direct analysis in real 
time (DART) 27,28 interfaces. 
12.2. Improvements in tandem mass 
spectrometry technology: Since LC–MS/MS 
technology is increasingly used for quantization 
in clinical science, as well as in other fields of 
science, there is a need for on-going 
improvements of the technology. A triple 
quadruple instrument in SRM mode is the 
instrument-of-choice in routine and high-
throughput quantitative clinical analysis. 
Commercial triple quadruple MS with 
atmospheric pressure ionization (API) sources 
are widely used nowadays. In the case of triple 
quadruple instruments the most commonly 
requested improvements were defined by 
Bennett to be: greater sensitivity, dynamic 
linear range, mass resolution, wider mass 
range, faster acquisition cycle time and reduced 
cost of ownership. Advances in triple quadruple 
technology are challenging and focus remains 
in the source and interface regions to improve 
ruggedness and reduce matrix effects. Some 
minor improvements in quadruple 
manufacturing processes and RF power supply 
stabilities enabled the production of a 
commercial system with enhanced mass 
resolution without significant losses in ion 
transmission 51,52. On the other hand significant 
instrumental developments were achieved in 
the last 10 years in the fields of other mass 
analysers like linear ion traps and HRMS like 
quadruple QTOF and FT-MS based 
instruments. Therefore the future of triple 
quadruples will be determined on the variable 
how extensively the clinical field adopts to high 
resolution, high mass accuracy instruments into 
their workflows and analytical requirements. 
Up to now, in case of triple quadruple 
instruments, mass resolution was typically 
ignored in favour of the outstanding linearity 
and increased sensitivity due to the selectivity 
offered by tandem MS. Now new tasks are 
gaining more and more interest where 
improved selectivity and full-scan data at low 
duty cycle times are crucial. 
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13. Schematic of a quadruple linear ion trap and description: 
 
 
 
Figure.6:TheTriplet OF MS technology features diagrammed.  
(a) A detailed illustration of the major platform features. (b) An image of the machined Triplet OF MS 
instrument platform.  
 
 
 
 
 
Ion mobility-mass spectrometry: Interfacing 
ion mobility spectrometry (IMS) with MS can 
provide significant advantages. The potential 
was understood early in the development of 
IMS, and the coupling of the two techniques is 
virtually as old as IMS itself. So ion mobility-
mass spectrometry (IMMS) cannot be 
regarded as new, but after the demonstration 
of protein conformer separation by Calmer et 
al. 1 there was a considerably increase in 
interest within this research area. During the 
last 10 years instruments became 
commercially available and both applications 
and instrumental designs of IMMS are now 
one of the most rapidly growing areas of MS. 
As a matter of fact numerous articles, reviews 
and even books} are dealing with the topic of 
IMMS. 
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Schematic of an ambient-pressure IMS(toff)MS. 
 
 
 
 
 
 
14. Progress in automation of LC-MS in 
laboratory medicine: 
Standard techniques of analyse detection in 
clinical chemistry rely on indirect characteristics 
of an analytic, e.g. its absorption of light, 
chemical reactivity or physical interaction with 
macro-molecules. In mass spectrometric 
methods, in contrast, analyses are detected 
directly from molecular characteristics as 
molecular mass and molecular disintegration 
patterns. Thus, mass spectrometric techniques 
are very attractive for the quantification of 
biomarkers or xenobiotic in the context of 
diagnostic procedures, since those techniques 
can enable analyses of much higher specificity 
compared to standard technologies such as 
photometry or ligand binding tests. With gas 
chromatography–mass spectrometry (GC–MS), 
first mass spectrometric methods were 
introduced to laboratory medicine about 40 
years ago. GC–MS allowed the highly specific 
and sensitive quantification of thermo-stable 
molecules below a molecular weight of about 
500. Thus, GC–MS became a key technology, 
e.g. in toxicology. With respect to 
standardization and quality assurance of small 
molecule analytical routine methods the 
introduction of GC–MS as a reference method 
was an essential progress, in particular for 
endocrinology. However, for several reasons the 
application of GC–MS remained restricted to 
few specialized institutions in laboratory 
medicine (mainly toxicological laboratories, 
metabolism centres, and reference laboratories). 
The handling and maintenance of GC–MS 
instruments is very demanding and time-
consuming; sample preparation is very laborious 
and includes sample extraction and analytic 
reprivatisation; the analytical run times are long 
with a typical sample throughput of less than 50 
samples per day 
 
15. Future of LC-MS/MS application in 
laboratory medicine: 
At present only rather few clinical laboratories 
worldwide are equipped with LC-MS/MS 
systems, and in these laboratories this 
technology typically makes up for less than 1% 
of all analyses. The success of efforts to 
substantially improve the practicability and 
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robustness of LC-MS/MS application by 
automation will be crucial for a more 
widespread application of this technology in the 
future. But is application of LC-MS/MS in 
laboratory medicine beyond the status quoi 
really reasonable? Indeed LC-MS/MS can close 
substantial gaps in the parameter portfolio of 
laboratory medicine 
LC-MS/MS can allow routine analyses on a 
reference method level of accuracy 
(incorporating isotope dilution technology) for 
important analysts for which immunoassays 
offer critically limited accuracy or cannot be 
applied at all (e.g., steroid hormones , plasma 
metanephrins, 25-hydroxyvitamin D, drug of 
abuse testing; methyl malonic acid, asymmetric 
dimethyl arginine, microbial antigens). 
LC-MS/MS can allow really comprehensive 
therapeutic drug monitoring (including 
assessment of metabolisation) for a personalized 
drug therapy; this is of utmost importance in the 
context of recent findings of pharmacokinetics 
for a large variety of drugs. The availability of 
companion testing will probably also becomes a 
key issue in the licensing of new drugs. 
LC-MS/MS enables highly multiplexed 
metabolic profiling which probably holds 
substantial potentials for disease monitoring. 
LCMS/ MS will probably be the analytical 
platform for all analyses which will be 
discovered to be useful in the context of 
metabolomics research. 
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